Saturday Rounds: Week of November 14–20, 2026

Hard endpoints win, gaps get rejected, markets fall. Weekly Biotech Signal Review · Completed reporting week: November 14–November 20, 2026 · Published November 21, 2026 Report at a glance: SELLAS reported a Phase 3 survival benefit in AML and the FDA approved four novel drugs,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *